Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Organ preservation in bladder cancer: an opportunity for truly personalized treatment.

Song YP, McWilliam A, Hoskin PJ, Choudhury A.

Nat Rev Urol. 2019 Jun 13. doi: 10.1038/s41585-019-0199-x. [Epub ahead of print] Review.

PMID:
31197260
2.

Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.

Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P, Townsend W, Culligan D, Popova B, Clifton-Hadley L, McMillan A, Hoskin P, O'Doherty MJ, Illidge T, Radford J.

J Clin Oncol. 2019 May 21:JCO1801799. doi: 10.1200/JCO.18.01799. [Epub ahead of print]

PMID:
31112475
3.

Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb).

Bhattacharya IS, Taghavi Azar Sharabiani M, Alonzi R, Hoskin PJ.

Radiother Oncol. 2019 May 3;137:38-44. doi: 10.1016/j.radonc.2019.04.019. [Epub ahead of print]

PMID:
31059955
4.

Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort.

Nomden CN, Pötter R, de Leeuw AAC, Tanderup K, Lindegaard JC, Schmid MP, Fortin I, Haie-Meder C, Mahantshetty U, Hoskin P, Segedin B, Bruheim K, Rai B, Huang F, Cooper R, Van Der Steen Banasik E, Van Limbergen E, Jürgenliemk-Schulz IM; EMBRACE Collaborative Group.

Radiother Oncol. 2019 May;134:185-190. doi: 10.1016/j.radonc.2019.02.007. Epub 2019 Feb 26.

5.

Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study.

Tan LT, Pötter R, Sturdza A, Fokdal L, Haie-Meder C, Schmid M, Gregory D, Petric P, Jürgenliemk-Schulz I, Gillham C, Van Limbergen E, Hoskin P, Tharavichitkul E, Villafranca E, Mahantshetty U, Kirisits C, Lindegaard J, Kirchheiner K, Tanderup K.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):895-902. doi: 10.1016/j.ijrobp.2019.03.038. Epub 2019 Mar 30.

PMID:
30940530
6.

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.

Walker AK, Karaszi K, Valentine H, Strauss VY, Choudhury A, McGill S, Wen K, Brown MD, Ramani V, Bhattarai S, Teo MTW, Yang L, Myers KA, Deshmukh N, Denley H, Browning L, Love SB, Iyer G, Clarke NW, Hall E, Huddart R, James ND, Hoskin PJ, West CML, Kiltie AE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):809-818. doi: 10.1016/j.ijrobp.2019.03.015. Epub 2019 Mar 15.

7.

Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues.

Choudhury A, Hoskin PJ.

Eur Urol. 2019 Jul;76(1):69-70. doi: 10.1016/j.eururo.2019.01.040. Epub 2019 Feb 4. No abstract available.

PMID:
30732925
8.

Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies.

Fokdal L, Tanderup K, Pötter R, Sturdza A, Kirchheiner K, Chargari C, Jürgenliemk-Schulz IM, Segedin B, Tan LT, Hoskin P, Mahantshetty U, Bruheim K, Rai B, Kirisits C, Lindegaard JC; EMBRACE Collaborative Group.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):887-894. doi: 10.1016/j.ijrobp.2018.11.006. Epub 2018 Nov 10.

PMID:
30419309
9.

Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity.

Dadhania S, Alonzi R, Douglas S, Gogbashian A, Hughes R, Dalili D, Vasdev N, Adshead J, Lane T, Westbury C, Anyamene N, Ostler P, Hoskin P, Sharma A.

Anticancer Res. 2018 Sep;38(9):5423-5427. doi: 10.21873/anticanres.12873.

PMID:
30194198
10.

Clinical trials targeting hypoxia.

Tharmalingham H, Hoskin P.

Br J Radiol. 2018 Jul 6:20170966. doi: 10.1259/bjr.20170966. [Epub ahead of print]

PMID:
29979089
11.

Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study.

Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, Mazeron R, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K; EMBRACE Collaborative Group.

Radiother Oncol. 2018 Jun;127(3):431-439. doi: 10.1016/j.radonc.2018.05.016. Epub 2018 Jun 4.

PMID:
29880222
12.

Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.

Christodoulou M, Reeves KJ, Hodgson C, Zeniou A, Slevin F, Kennedy J, Hoskin PJ, Henry A, Choudhury A.

Radiother Oncol. 2018 Dec;129(3):499-506. doi: 10.1016/j.radonc.2018.05.022. Epub 2018 Jun 2.

13.

Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer.

Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K.

Radiother Oncol. 2018 Jun;127(3):423-430. doi: 10.1016/j.radonc.2018.05.002. Epub 2018 May 18.

PMID:
29784450
14.

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.

EBioMedicine. 2018 May;31:182-189. doi: 10.1016/j.ebiom.2018.04.019. Epub 2018 Apr 23.

15.

Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study.

Najjari Jamal D, Pötter R, Haie-Meder C, Lindegaard JC, Juergenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Wiebe E, Cooper R, Tanderup K, Kirchheiner K; EMBRACE collaborative group.

Radiother Oncol. 2018 Jun;127(3):449-455. doi: 10.1016/j.radonc.2018.03.026. Epub 2018 Apr 6.

PMID:
29631933
16.

Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: An analysis from the EMBRACE study.

Smet S, Pötter R, Haie-Meder C, Lindegaard JC, Schulz-Juergenliemk I, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van Limbergen E, Tanderup K, Kirchheiner K; EMBRACE Collaborative Group.

Radiother Oncol. 2018 Jun;127(3):440-448. doi: 10.1016/j.radonc.2018.03.009. Epub 2018 Apr 5.

PMID:
29627137
17.

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.

Pötter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B, Hoskin P, Bruheim K, Rai B, Huang F, Van Limbergen E, Schmid M, Nesvacil N, Sturdza A, Fokdal L, Jensen NBK, Georg D, Assenholt M, Seppenwoolde Y, Nomden C, Fortin I, Chopra S, van der Heide U, Rumpold T, Lindegaard JC, Jürgenliemk-Schulz I; EMBRACE Collaborative Group.

Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60. doi: 10.1016/j.ctro.2018.01.001. eCollection 2018 Feb. Review.

18.

ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer.

Salembier C, Villeirs G, De Bari B, Hoskin P, Pieters BR, Van Vulpen M, Khoo V, Henry A, Bossi A, De Meerleer G, Fonteyne V.

Radiother Oncol. 2018 Apr;127(1):49-61. doi: 10.1016/j.radonc.2018.01.014.

PMID:
29496279
19.

Bladder cancer and the National Cancer Data Base: New insight or misinformation?

Choudhury A, Hoskin PJ.

Cancer. 2018 Mar 15;124(6):1105-1107. doi: 10.1002/cncr.31210. Epub 2018 Jan 16. No abstract available.

20.

Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.

Raman S, Ding K, Chow E, Meyer RM, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, Haas R, Wiggenraad R, Babington S, Demas WF, Wilson CF, Wong RKS, Zhu L, Brundage M.

Qual Life Res. 2018 Apr;27(4):1089-1098. doi: 10.1007/s11136-017-1745-8. Epub 2017 Nov 29.

PMID:
29188483
21.

Focal boost to residual gross tumor volume in brachytherapy for cervical cancer-A feasibility study.

Thiruthaneeswaran N, Groom N, Lowe G, Bryant L, Hoskin PJ.

Brachytherapy. 2018 Jan - Feb;17(1):181-186. doi: 10.1016/j.brachy.2017.09.012. Epub 2017 Nov 15.

PMID:
29153466
22.

Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial.

Chow R, Ding K, Ganesh V, Meyer RM, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, van Acht M, Wanders R, Babington S, Demas WF, Wilson CF, Wong RKS, Brundage M, Zhu L, Chow E.

Radiother Oncol. 2018 Mar;126(3):541-546. doi: 10.1016/j.radonc.2017.10.006. Epub 2017 Nov 5.

PMID:
29102263
23.

The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.

Prettyjohns M, Hoskin P, McNamara C, Linch D; NICE non-Hodgkin Lymphoma Clinical Guideline Committee.

Br J Haematol. 2018 Jan;180(1):52-59. doi: 10.1111/bjh.14990. Epub 2017 Oct 26.

PMID:
29076139
24.

The optimism surrounding stereotactic body radiation therapy and immunomodulation.

Tharmalingam H, Hoskin PJ.

Chin Clin Oncol. 2017 Sep;6(Suppl 2):S9. doi: 10.21037/cco.2017.05.01. Review.

25.

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.

Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J.

Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478. Epub 2017 Sep 14. Review.

26.

A restatement of the natural science evidence base concerning the health effects of low-level ionizing radiation.

McLean AR, Adlen EK, Cardis E, Elliott A, Goodhead DT, Harms-Ringdahl M, Hendry JH, Hoskin P, Jeggo PA, Mackay DJC, Muirhead CR, Shepherd J, Shore RE, Thomas GA, Wakeford R, Godfray HCJ.

Proc Biol Sci. 2017 Sep 13;284(1862). pii: 20171070. doi: 10.1098/rspb.2017.1070. Review.

27.

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.

Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516-X. doi: 10.1016/j.eururo.2017.06.021. [Epub ahead of print]

28.

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.

Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G.

Radiother Oncol. 2017 Jul;124(1):56-60. doi: 10.1016/j.radonc.2017.06.014. Epub 2017 Jun 27.

PMID:
28666552
29.

The evolution of brachytherapy for prostate cancer.

Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, Morton GC, Horwitz EM.

Nat Rev Urol. 2017 Jun 30;14(7):415-439. doi: 10.1038/nrurol.2017.76. Review.

PMID:
28664931
30.

A review of patterns of practice and clinical guidelines in the palliative radiation treatment of uncomplicated bone metastases.

Ganesh V, Chan S, Raman S, Chow R, Hoskin P, Lam H, Wan BA, Drost L, DeAngelis C, Chow E.

Radiother Oncol. 2017 Jul;124(1):38-44. doi: 10.1016/j.radonc.2017.06.002. Epub 2017 Jun 16. Review.

PMID:
28629871
31.

Treat All Known Disease.

Hoskin PJ.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):494. doi: 10.1016/j.ijrobp.2016.12.006. No abstract available.

PMID:
28581386
32.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators.

N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3.

33.

A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.

Yang L, Taylor J, Eustace A, Irlam JJ, Denley H, Hoskin PJ, Alsner J, Buffa FM, Harris AL, Choudhury A, West CML.

Clin Cancer Res. 2017 Aug 15;23(16):4761-4768. doi: 10.1158/1078-0432.CCR-17-0038. Epub 2017 Apr 11.

34.

Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis.

Chow R, Hoskin P, Hollenberg D, Lam M, Dennis K, Lutz S, Lam H, Mesci A, DeAngelis C, Chan S, Chow E.

Ann Palliat Med. 2017 Apr;6(2):125-142. doi: 10.21037/apm.2016.12.04. Epub 2017 Jan 9. Review.

35.

Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review.

Chow R, Hoskin P, Chan S, Mesci A, Hollenberg D, Lam H, DeAngelis C, Chow E.

Radiother Oncol. 2017 Mar;122(3):323-331. doi: 10.1016/j.radonc.2016.12.031. Epub 2017 Jan 12. Review.

PMID:
28089482
36.

How should radiation oncologists interpret the ASTRO evidence-based guideline and ASTRO Choosing Wisely campaign for the treatment of uncomplicated bone metastases?

Raman S, Chow R, Hoskin P, Chow E.

Pract Radiat Oncol. 2017 Jan - Feb;7(1):13-15. doi: 10.1016/j.prro.2016.09.008. Epub 2016 Sep 29. No abstract available.

PMID:
28029605
37.

The dosimetric impact of air in vaginal vault brachytherapy.

Maxwell Á, Thiruthaneeswaran N, Lowe G, Wills R, Sripali S, Hoskin PJ.

Brachytherapy. 2016 Nov - Dec;15(6):832-838. doi: 10.1016/j.brachy.2016.08.006. Epub 2016 Sep 29.

PMID:
27693171
38.

Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.

Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Šegedin B, Mahantshetty U, Hoskin P, Jürgenliemk-Schulz I, Kirisits C, Lindegaard JC, Dörr W, Haie-Meder C, Tanderup K, Pötter R; EMBRACE collaborative group.

Radiother Oncol. 2016 Sep;120(3):412-419. doi: 10.1016/j.radonc.2016.06.006. Epub 2016 Jul 7.

PMID:
27396811
39.

Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.

Murray L, Mason J, Henry AM, Hoskin P, Siebert FA, Venselaar J, Bownes P; UroGEC/BRAPHYQS group of the GEC ESTRO.

Radiother Oncol. 2016 Aug;120(2):293-9. doi: 10.1016/j.radonc.2016.05.026. Epub 2016 Jun 29.

40.

Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer.

Tanderup K, Fokdal LU, Sturdza A, Haie-Meder C, Mazeron R, van Limbergen E, Jürgenliemk-Schulz I, Petric P, Hoskin P, Dörr W, Bentzen SM, Kirisits C, Lindegaard JC, Pötter R.

Radiother Oncol. 2016 Sep;120(3):441-446. doi: 10.1016/j.radonc.2016.05.014. Epub 2016 Jun 24. Erratum in: Radiother Oncol. 2017 Apr;123(1):169.

PMID:
27350396
41.

Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.

Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Šegedin B, Jurgenliemk-Schulz IM, Nomden C, Gillham C, McArdle O, Van Limbergen E, Janssen H, Hoskin P, Lowe G, Tharavichitkul E, Villafranca E, Mahantshetty U, Georg P, Kirchheiner K, Kirisits C, Tanderup K, Lindegaard JC.

Radiother Oncol. 2016 Sep;120(3):428-433. doi: 10.1016/j.radonc.2016.03.011. Epub 2016 Apr 29.

PMID:
27134181
42.

Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study.

Fokdal L, Sturdza A, Mazeron R, Haie-Meder C, Tan LT, Gillham C, Šegedin B, Jürgenliemk-Schultz I, Kirisits C, Hoskin P, Pötter R, Lindegaard JC, Tanderup K.

Radiother Oncol. 2016 Sep;120(3):434-440. doi: 10.1016/j.radonc.2016.03.020. Epub 2016 Apr 21.

PMID:
27113795
43.

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C.

Prostate. 2016 Jul;76(10):905-16. doi: 10.1002/pros.23180. Epub 2016 Mar 23.

44.

Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Glynne-Jones R, Tan D, Hughes R, Hoskin P.

Nat Rev Clin Oncol. 2016 Jul;13(7):447-59. doi: 10.1038/nrclinonc.2015.218. Epub 2016 Jan 27. Review.

PMID:
26813935
45.

Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.

Kirchheiner K, Nout RA, Lindegaard JC, Haie-Meder C, Mahantshetty U, Segedin B, Jürgenliemk-Schulz IM, Hoskin PJ, Rai B, Dörr W, Kirisits C, Bentzen SM, Pötter R, Tanderup K; EMBRACE Collaborative Group.

Radiother Oncol. 2016 Jan;118(1):160-6. doi: 10.1016/j.radonc.2015.12.025. Epub 2016 Jan 9.

PMID:
26780997
46.

Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain.

Fallon M, Hoskin PJ, Colvin LA, Fleetwood-Walker SM, Adamson D, Byrne A, Murray GD, Laird BJ.

J Clin Oncol. 2016 Feb 20;34(6):550-6. doi: 10.1200/JCO.2015.63.8221. Epub 2015 Dec 7.

47.

A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study.

Kaljouw E, Pieters BR, Kovács G, Hoskin PJ.

Radiother Oncol. 2016 Jan;118(1):122-30. doi: 10.1016/j.radonc.2015.10.021. Epub 2015 Nov 5.

PMID:
26549865
48.

Predictive model for survival in patients having repeat radiation treatment for painful bone metastases.

Chow E, Ding K, Parulekar WR, Wong RK, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Nabid A, Leer JW, Vonk E, Babington S, Demas WF, Wilson CF, Brundage M, Zhu L, Meyer RM.

Radiother Oncol. 2016 Mar;118(3):547-51. doi: 10.1016/j.radonc.2015.10.018. Epub 2015 Oct 26.

PMID:
26515411
49.

Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life.

Chow E, Ding K, Parulekar WR, Wong RK, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Nabid A, Ong F, van Tienhoven G, Babington S, Demas WF, Wilson CF, Brundage M, Zhu L, Meyer RM.

Support Care Cancer. 2016 Apr;24(4):1617-23. doi: 10.1007/s00520-015-2957-5. Epub 2015 Sep 23.

PMID:
26399406
50.

A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.

Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A.

J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197. Print 2015 Oct.

PMID:
26242893

Supplemental Content

Loading ...
Support Center